Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S011000, C544S353000, C546S167000, C546S268100, C548S202000, C548S247000, C548S373100, C549S059000
Reexamination Certificate
active
07875618
ABSTRACT:
The invention relates to imidazo[1,5-a]quinoxaline derivatives having Formula IIa:to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.
REFERENCES:
patent: 5034530 (1991-07-01), Hansen et al.
patent: 5055465 (1991-10-01), Davey
patent: 6235740 (2001-05-01), Barrish et al.
patent: 6239133 (2001-05-01), Barrish et al.
patent: 6326375 (2001-12-01), Fukami et al.
patent: 6335345 (2002-01-01), Fukami et al.
patent: 6566367 (2003-05-01), Bakthavatchalam et al.
patent: 7550465 (2009-06-01), Höefgen et al.
patent: 2002/0151456 (2002-10-01), Song et al.
patent: 2003/0036652 (2003-02-01), Bakthavatchalam et al.
patent: 2003/0032579 (2003-03-01), Lebel et al.
patent: 2007/0032404 (2007-02-01), Sweet
patent: 2007/0299079 (2007-12-01), Norbert et al.
patent: 2008/0027064 (2008-01-01), Hoefgen et al.
patent: 2009/0143361 (2009-06-01), Malamas et al.
patent: 2009/0143391 (2009-06-01), Hoefgen et al.
patent: 2009/0143392 (2009-06-01), Hoefgen et al.
patent: 2009/0239874 (2009-09-01), Hoefgen et al.
patent: 2010/0120762 (2010-05-01), Stange et al.
patent: 2010/0120763 (2010-05-01), Stange et al.
patent: 0 347 094 (1989-12-01), None
patent: 0 736 532 (1996-09-01), None
patent: 0 400 583 (1999-05-01), None
patent: WO 92/22552 (1992-12-01), None
patent: WO 99/09845 (1999-03-01), None
patent: WO 99/45009 (1999-09-01), None
patent: WO 00/43392 (2000-07-01), None
patent: WO 00/56719 (2000-09-01), None
patent: WO 01/68097 (2001-09-01), None
patent: WO 03/010175 (2003-02-01), None
patent: WO 03/082190 (2003-10-01), None
patent: WO 2005/014595 (2005-02-01), None
patent: WO 2005/087919 (2005-09-01), None
patent: WO 2005/120514 (2005-12-01), None
patent: WO 2006/089815 (2006-08-01), None
patent: WO 2007/137819 (2007-12-01), None
patent: WO 2007/137820 (2007-12-01), None
patent: WO 2009/068246 (2009-06-01), None
patent: WO 2009/070583 (2009-06-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Abi-Saab et al.,Pharmacopsychiatry31 Suppl 2: 104-109, 1998.
Alberti et al.,Diabetic Medicine, 15, 539-553, 1998.
Berge,Journal of Pharmaceutical Science, 66, 2, 1977.
Capuano et al.,Curr Med Chem9: 521-548, 2002.
Castner et al.,Science287: 2020-2022, 2000.
Chen et al.,Bioorg. Med. Chem. Lett. 12, 1361-1364, 2002.
Chen et al.,Bioorg. Med. Chem. Lett. 12, 3153-3156, 2002.
Chen et al.,J Med. Chem. 47:4517-4545, 2004.
Colota et al.,Eur.J. Med Chem, 30, 133-139, 1995.
Davey et al.J Med. Chem., 34, 2671-2677, 1991.
Essayan,J Allergy Clin Immunol108: 671-680, 2001.
Garver et al.,Life Sci31: 1987-1992, 1982.
Gattaz et al.,Biol Psychiatry19: 1229-1235, 1984.
Database CAPLUS on STN, No. 113:212016, 1990.
Database CAPLUS on STN, No. 113:115337, 1990.
Database CAPLUS on STN, No. 144:22920, 2005.
Database CAPLUS on STN, No. 141:277643, 2004.
Database CAPLUS on STN, No. 147:211834, 2007.
Database CAPLUS on STN, No. 122:305875, 1995.
Database CAPLUS on STN, No. 130:223296, 1999.
Database CAPLUS on STN, No. 99:22496, 1983.
Jentsch and Roth,Neuropsychopharmacology20: 201-225, 1999.
Kaiya,Prostaglandins Leukot Essent Fatty Acids46: 33-38, 1992.
Kehler, et al., Expert Opinion, pp. 47-158, 2007.
Kostowski et al.Pharmacol Biochem Behav5: 15-17, 1976.
Kotera et al.,Biochem Biophys Res Commun261: 551-557, 1999.
Lahti et al.,Neuropsychopharmacology25: 455-467, 2001.
Lapiz et al.,Neurosci Behav Physiol33: 13-29, 2003.
Leveque et al.,J Neurosci20: 4011-4020, 2000.
Lindenmayer et al.,J Clin Psychiatry63: 931-935, 2002.
Millan,Prog Neurobiol70: 83-244, 2005.
Muly,Psychopharmacol Bull36: 92-105, 2002.
Mutschler et al.,Mutschler Arzneimittelwirkungen. 8thed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2001.
Norris, D. et al. (Tetrahedron Letters 42, 4297-4299, 2001.
Nyberg et al.,Psychopharmacology162: 37-41, 2002.
Remington's Pharmaceutical Sciences, 17thed., Mack Publishing Company, Easton, Pa., p. 1418, 1985.
Rodefer et al.Eur.J Neurosci21: 1070-1076, 2005.
Sawaguchi,Parkinsonism Relat Disord7: 9-19, 2000.
Suzuki,Pure&Appl. Chem., 57, 1749, 1985.
Soderling et al.,Curr. Opin. Cell Biol12: 174-179, 1999.
Soderling et al.,Proc Natl Acad USA96(12):7071-7076, 2000.
Sonogashira,Synthesis, 777, 1977.
Sundaram et al.,J Org. Chem., 72(13), 5020-5023, 2007.
The Evidence Report, Washington, DC:U.S. Department of Health and Human Services, NIH publication No. 98-4083,1998.
William Harvey Research Conference, Porto, Dec. 6th-8th, 2001.
Wong, G. et al.,European Journal of Pharmacology Molecular Pharmacology Section, 289, 335-342, 1995.
Xie et al.,Neuroscience139: 597-607, 2006.
International Search Report and Written Opinion, dated Feb. 24, 2009, issued in International Application No. PCT/US2008/084688.
International Search Report and Written Opinion, dated Feb. 9, 2009, issued in International Application No. PCT/US2008/084689.
International Search Report and Written Opinion, dated Jun. 15, 2009, issued in International Application No. PCT/EP2008/009990.
Gupta et al.,Methods and Findings in Experimental and Clinical Pharmacology, 27: 101-118, 2005.
Non-final office action received May 28, 2010 for U.S. Appl. No. 12/277,961, 16 pages.
Non-final office action received Jun. 16, 2010 for U.S. Appl. No. 12/323,188, 20 pages.
International Search Report and Written Opinion, dated Feb. 24, 2009, issued in International Application No. PCT/US2008/084688, 17 pages.
International Search Report and Written Opinion, dated Mar. 10, 2010, issued in International Application No. PCT/US2009/063633, 30 pages.
International Search Report and Written Opinion, dated Feb. 8, 2010, issued in International Application No. PCT/US2009/063642, 67 pages.
International Search Report and Written Opinion, dated Feb. 8, 2010, issued in International Application No. PCT/EP2008/009990, 382 pages.
Sonogashira, K. In Comprehensive Organic Synthesis; Trost, B.M.; Fleming, I.; Eds.; Pergamon Press: Oxford, 1991, vol. 3, Chapters 2,4; pp. 521-549.
Egerland Ute
Erdei James Joseph
Höfgen Norbert
Langen Barbara
Malamas Michael S.
elbion GmbH
Fish & Richardson P.C.
Willis Douglas M
Wilson James O
Wyeth
LandOfFree
Substituted imidazo[1,5-a]quinoxalines useful as inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted imidazo[1,5-a]quinoxalines useful as inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted imidazo[1,5-a]quinoxalines useful as inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707260